These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 31348600)

  • 1. Evaluation of the antitumor mechanism of antibody-drug conjugates against tissue factor in stroma-rich allograft models.
    Tsumura R; Manabe S; Takashima H; Koga Y; Yasunaga M; Matsumura Y
    Cancer Sci; 2019 Oct; 110(10):3296-3305. PubMed ID: 31348600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effect of humanized anti‑tissue factor antibody‑drug conjugate in a model of peritoneal disseminated pancreatic cancer.
    Tsumura R; Anzai T; Manabe S; Takashima H; Koga Y; Yasunaga M; Matsumura Y
    Oncol Rep; 2021 Jan; 45(1):329-336. PubMed ID: 33200231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts.
    Koga Y; Manabe S; Aihara Y; Sato R; Tsumura R; Iwafuji H; Furuya F; Fuchigami H; Fujiwara Y; Hisada Y; Yamamoto Y; Yasunaga M; Matsumura Y
    Int J Cancer; 2015 Sep; 137(6):1457-66. PubMed ID: 25704403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of the dissociation rate constant on the intra-tumor distribution of antibody-drug conjugate against tissue factor.
    Tsumura R; Manabe S; Takashima H; Koga Y; Yasunaga M; Matsumura Y
    J Control Release; 2018 Aug; 284():49-56. PubMed ID: 29906553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced antitumor effect of anti-tissue factor antibody-conjugated epirubicin-incorporating micelles in xenograft models.
    Yamamoto Y; Hyodo I; Koga Y; Tsumura R; Sato R; Obonai T; Fuchigami H; Furuya F; Yasunaga M; Harada M; Kato Y; Ohtsu A; Matsumura Y
    Cancer Sci; 2015 May; 106(5):627-34. PubMed ID: 25711681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110.
    Domínguez JM; Pérez-Chacón G; Guillén MJ; Muñoz-Alonso MJ; Somovilla-Crespo B; Cibrián D; Acosta-Iborra B; Adrados M; Muñoz-Calleja C; Cuevas C; Sánchez-Madrid F; Avilés P; Zapata JM
    J Hematol Oncol; 2020 Apr; 13(1):32. PubMed ID: 32264921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells.
    Singh R; Setiady YY; Ponte J; Kovtun YV; Lai KC; Hong EE; Fishkin N; Dong L; Jones GE; Coccia JA; Lanieri L; Veale K; Costoplus JA; Skaletskaya A; Gabriel R; Salomon P; Wu R; Qiu Q; Erickson HK; Lambert JM; Chari RV; Widdison WC
    Mol Cancer Ther; 2016 Jun; 15(6):1311-20. PubMed ID: 27197308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer.
    Bourillon L; Bourgier C; Gaborit N; Garambois V; Llès E; Zampieri A; Ogier C; Jarlier M; Radosevic-Robin N; Orsetti B; Delpech H; Theillet C; Colombo PE; Azria D; Pèlegrin A; Larbouret C; Chardès T
    Int J Cancer; 2019 Oct; 145(7):1838-1851. PubMed ID: 30882895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates.
    Burke PJ; Hamilton JZ; Jeffrey SC; Hunter JH; Doronina SO; Okeley NM; Miyamoto JB; Anderson ME; Stone IJ; Ulrich ML; Simmons JK; McKinney EE; Senter PD; Lyon RP
    Mol Cancer Ther; 2017 Jan; 16(1):116-123. PubMed ID: 28062707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma.
    Munekage E; Serada S; Tsujii S; Yokota K; Kiuchi K; Tominaga K; Fujimoto M; Kanda M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T
    Neoplasia; 2021 Sep; 23(9):939-950. PubMed ID: 34332450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
    Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
    J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues.
    Zhang D; Dragovich PS; Yu SF; Ma Y; Pillow TH; Sadowsky JD; Su D; Wang W; Polson A; Khojasteh SC; Hop CECA
    Drug Metab Dispos; 2019 Oct; 47(10):1146-1155. PubMed ID: 31358513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E.
    Wang Y; Zhang X; Fan J; Chen W; Luan J; Nan Y; Wang S; Chen Q; Zhang Y; Wu Y; Ju D
    Front Immunol; 2018; 9():1799. PubMed ID: 30123222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumor activity of antibody drug conjugate targeting aspartate-β-hydroxylase in pancreatic ductal adenocarcinoma.
    Nagaoka K; Bai X; Ogawa K; Dong X; Zhang S; Zhou Y; Carlson RI; Jiang ZG; Fuller S; Lebowitz MS; Ghanbari H; Wands JR
    Cancer Lett; 2019 May; 449():87-98. PubMed ID: 30768955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-terminal selective conjugation method widens the therapeutic window of antibody-drug conjugates by improving tolerability and stability.
    Ko MJ; Song D; Kim J; Kim JY; Eom J; Sung B; Son YG; Kim YM; Lee SH; You WK; Jung J
    MAbs; 2021; 13(1):1914885. PubMed ID: 33904380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
    Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
    Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates.
    Costa MJ; Kudaravalli J; Ma JT; Ho WH; Delaria K; Holz C; Stauffer A; Chunyk AG; Zong Q; Blasi E; Buetow B; Tran TT; Lindquist K; Dorywalska M; Rajpal A; Shelton DL; Strop P; Liu SH
    Sci Rep; 2019 Feb; 9(1):2443. PubMed ID: 30792442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Near-infrared photoimmunotherapy of pancreatic cancer using an indocyanine green-labeled anti-tissue factor antibody.
    Aung W; Tsuji AB; Sugyo A; Takashima H; Yasunaga M; Matsumura Y; Higashi T
    World J Gastroenterol; 2018 Dec; 24(48):5491-5504. PubMed ID: 30622378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LILRB4-targeting Antibody-Drug Conjugates for the Treatment of Acute Myeloid Leukemia.
    Anami Y; Deng M; Gui X; Yamaguchi A; Yamazaki CM; Zhang N; Zhang CC; An Z; Tsuchikama K
    Mol Cancer Ther; 2020 Nov; 19(11):2330-2339. PubMed ID: 32879051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors.
    Breij EC; de Goeij BE; Verploegen S; Schuurhuis DH; Amirkhosravi A; Francis J; Miller VB; Houtkamp M; Bleeker WK; Satijn D; Parren PW
    Cancer Res; 2014 Feb; 74(4):1214-26. PubMed ID: 24371232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.